CBD May Help Resolve Inflammation by Shifting Immune Cells Toward Pro-Resolving Signals

A 2023 study identified a possible molecular explanation for cannabidiol’s (CBD) anti-inflammatory effects: rather than simply blocking inflammation, CBD may encourage immune cells to produce signals that help bring the inflammatory response to an end.

Published in Cell Chemical Biology, the research examined eight cannabis-derived cannabinoids, including CBD, tetrahydrocannabinol (THC), and cannabigerol (CBG). The work was led by researchers at Friedrich Schiller University Jena and collaborating institutions.

Inflammation is a normal part of the immune response. It helps the body respond to injury and infection, but a response that persists or becomes excessive can contribute to tissue damage and chronic disease. The researchers focused on lipid mediators—fat-derived signaling molecules that regulate different stages of inflammation.

Some lipid mediators promote inflammation, including leukotrienes. Others, known as specialized pro-resolving mediators, or SPMs, help shut down the response and support a return to normal tissue function. The study investigated whether cannabinoids influence the balance between these two groups.

In experiments using human monocyte-derived macrophages, CBD emerged as the most effective of the eight cannabinoids tested. It increased the production of SPMs while suppressing the formation of inflammatory leukotrienes. The researchers described this as a “lipid mediator class switch”—a change in the cells’ biochemical activity that favors resolution rather than continued inflammation.

The team linked the effect in part to 15-lipoxygenase-1, or 15-LOX-1. Their results suggest that CBD can activate this enzyme through an allosteric mechanism, helping it generate inflammation-resolving compounds. At the same time, CBD inhibited the 5-lipoxygenase pathway involved in producing leukotrienes.

The findings were also tested in mice with zymosan-induced peritonitis, an experimental model of acute inflammation. In that model, CBD increased SPM-related products and reduced levels of several pro-inflammatory eicosanoids. These animal results supported the cell-culture findings, but they did not establish that CBD treats inflammatory diseases in people.

The study is important because it points to a mechanism beyond the commonly cited interaction between cannabinoids and CB1 or CB2 receptors. CBD has relatively complex pharmacology, and its effects may vary according to the cell type, dose, formulation, and biological pathway involved. The research specifically supports a role for lipid-mediator regulation and 15-LOX-1 activation; it does not show that CBD is a proven treatment for chronic pain, autoimmune disease, cardiovascular disease, or skin conditions.

Nor was the study a clinical trial of CBD products. The experiments used isolated human immune cells and a mouse model, so further research is needed to determine whether the same pathway operates reliably in people and whether it produces meaningful health benefits at safe, clinically practical doses.

Consumers should also distinguish between experimental findings and approved medical uses. The U.S. Food and Drug Administration has approved one purified CBD prescription drug, Epidiolex, for certain severe seizure disorders—not as a general anti-inflammatory treatment. The agency warns that CBD can cause liver injury, interact with other medicines, and carry other risks, particularly when used without medical supervision. Its guidance on cannabis- and CBD-derived products also notes that most commercially marketed CBD products have not been evaluated for effectiveness, dosage, or quality.

Overall, the 2023 study offers a plausible biochemical explanation for some of CBD’s observed anti-inflammatory activity. By encouraging immune cells to shift from producing inflammation-promoting molecules toward compounds that help resolve inflammation, CBD may provide a useful starting point for future drug development. Whether that mechanism can be translated into safe and effective treatments remains an open question for clinical research.